Approval of bonus issue at Dr. Reddy's 22nd Annual General Meeting.HYDERABAD, India -- Dr. Reddy's today announced that at the 22nd Annual General Meeting held on July 28, 2006, the shareholders have approved issue of bonus equity shares in the ratio of 1:1 (one equity share for each equity share held) for all existing shares including American Depository The place where a deposit is placed and kept, e.g., a bank, savings and loan institution, credit union, or trust company. A place where something is deposited or stored as for safekeeping or convenience, e.g., a safety deposit box. Shares. The Company has announced August 29, 2006 as record date for determining the eligibility of the shareholders for the bonus shares. Earlier, the Board of Directors at their meeting held on May 31, 2006, recommended issue of bonus shares in proportion of one share for every one equity share held by the members on the record date. About Dr. Reddy's Established in 1984, Dr. Reddy's Laboratories Dr. Reddy’s Laboratories Ltd. (Reddy's), founded in 1984 by Dr. K. Anji Reddy, has become India’s third biggest pharmaceutical company. Reddy had worked in the publicly-owned Indian Drugs and Pharmaceuticals Ltd. (NYSE NYSE See: New York Stock Exchange : RDY RDY Ready ) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms A dosage form is the physical form of a dose of medication, such as a capsule or injection. The route of administration is dependent on the dosage form of a given drug. , active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer. Disclaimer This press release includes forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. , as defined in the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion